<p>Adagene Inc. 赞助的 ADR (NASDAQ:ADAG - 免费报告) - HC Wainwright 的股票研究分析师在 4 月 7 日星期二发布的研究报告中发布了对 Adagene 2026 财年的盈利预测。HC Wainwright 的分析师 A. He 预测该公司将在本年度每股收益为（$0.37）。Adagene 当前全年的共识盈利预测为每股（$0.60）。HC Wainwright 还发布了对 Adagene 2027 财年每股收益的预测为（$0.44），2028 财年每股收益为（$0.74），2029 财年每股收益为（$1.13）以及 2030 财年每股收益为（$0.92）。</p>
<p>ADAG 还受到其他几份研究报告的关注。Weiss Ratings 在 1 月 21 日星期三的研究报告中重申了对 Adagene 股票的 &#34;卖出（d-）&#34;评级。华尔街 Zen 在 3 月 21 日星期六的研究报告中将 Adagene 股票的评级上调至 &#34;持有&#34;。最后，Guggenheim 在周一的研究报告中将 Adagene 股票的目标价格从 $9.00 提高至 $10.00，并给予该公司 &#34;买入&#34;评级。两位股票研究分析师给予该股票 &#34;强烈买入&#34;评级，两位给予 &#34;买入&#34;评级，一位给予 &#34;卖出&#34;评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;买入&#34;，共识目标价格为 $8.00。</p>
<p><strong>阅读我们关于 Adagene 的最新股票报告</strong></p>
<h2>Adagene 股票表现</h2>
<p>NASDAQ:ADAG 的股票在星期四开盘时为 $4.00。该公司的 50 日简单移动平均线为 $3.40，200 日简单移动平均线为 $2.41。Adagene 的 12 个月低点为 $1.30，12 个月高点为 $4.75。</p>
<p>Adagene (NASDAQ:ADAG - 获取免费报告) 最近在 4 月 1 日星期三发布了季度财报。该公司报告的每股收益为（$0.04），超出分析师的共识预期（$0.28）$0.24。该季度的收入为 $3.84 百万，而共识预期为 $17.50 百万。</p>
<h2>Adagene 的机构交易</h2>
<p>机构投资者最近增加或减少了对该公司的持股。Marex Group plc 在第二季度购买了价值 $47,000 的 Adagene 新股份。SmartHarvest Portfolios LLC 在第四季度购买了价值约 $73,000 的 Adagene 新股份。Citadel Advisors LLC 在第三季度购买了价值约 $80,000 的 Adagene 新股份。Gordian Capital Singapore Pte Ltd 在第三季度将其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 目前拥有 48,342 股该公司的股票，价值 $96,000，此前在上个季度增持了 24,342 股。最后，Fifth Lane Capital LP 在第四季度将其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 目前拥有 145,000 股该公司的股票，价值 $274,000，此前在上个季度增持了 117,500 股。机构投资者持有该公司 9.51% 的股份。</p>
<h2>Adagene 公司简介</h2>
<p>(获取免费报告)</p>
<p>Adagene Inc. 总部位于中国苏州，是一家临床阶段的生物制药公司，专注于抗体基础治疗的发现和开发，主要用于癌症和免疫相关疾病。公司成立于 2017 年，利用其专有的免疫组学技术平台挖掘人类抗体库，并设计新型单特异性和双特异性抗体。Adagene 的产品线包括多个处于临床前和早期临床开发阶段的候选药物，重点是针对肿瘤微环境和调节免疫检查点以增强抗肿瘤疗效。</p>
<p>Adagene 研发工作的核心是其 Bihanc™ 抗体平台，该平台结合了组合噬菌体展示、基于结构的设计和人工智能，以优化结合亲和力、特异性和开发性。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Adagene</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Adagene 吗？</h2>
<p>在你考虑 Adagene 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Adagene 并不在名单上。</p>
<p>虽然 Adagene 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

天演药业

<p>Adagene Inc.（纳斯达克代码：ADAG）收到了 HC Wainwright 对 2026 财年的收益预测，预计每股亏损为（$0.37），而市场共识预测为（$0.60）。未来的收益预测包括 2027 财年（$0.44）和 2028 财年（$0.74）。该股票目前的平均评级为 “买入”，目标价格为$8.00。最近的交易显示，股票开盘价为$4.00，12 个月的价格区间为$1.30 至$4.75。机构投资者持有该公司 9.51% 的股份，该公司专注于癌症的抗体治疗</p>

<p>Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share for the year. The consensus estimate for Adagene's current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Adagene's FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($1.13) EPS and FY2030 earnings at ($0.92) EPS.</p>
<div class="lb-trans"><p>Adagene Inc. 赞助的 ADR (NASDAQ:ADAG - 免费报告) - HC Wainwright 的股票研究分析师在 4 月 7 日星期二发布的研究报告中发布了对 Adagene 2026 财年的盈利预测。HC Wainwright 的分析师 A. He 预测该公司将在本年度每股收益为（$0.37）。Adagene 当前全年的共识盈利预测为每股（$0.60）。HC Wainwright 还发布了对 Adagene 2027 财年每股收益的预测为（$0.44），2028 财年每股收益为（$0.74），2029 财年每股收益为（$1.13）以及 2030 财年每股收益为（$0.92）。</p>
</div><p>ADAG has been the subject of several other research reports. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adagene in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Adagene to a &#34;hold&#34; rating in a research note on Saturday, March 21st. Finally, Guggenheim boosted their target price on shares of Adagene from $9.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>ADAG 还受到其他几份研究报告的关注。Weiss Ratings 在 1 月 21 日星期三的研究报告中重申了对 Adagene 股票的 &#34;卖出（d-）&#34;评级。华尔街 Zen 在 3 月 21 日星期六的研究报告中将 Adagene 股票的评级上调至 &#34;持有&#34;。最后，Guggenheim 在周一的研究报告中将 Adagene 股票的目标价格从 $9.00 提高至 $10.00，并给予该公司 &#34;买入&#34;评级。两位股票研究分析师给予该股票 &#34;强烈买入&#34;评级，两位给予 &#34;买入&#34;评级，一位给予 &#34;卖出&#34;评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;买入&#34;，共识目标价格为 $8.00。</p>
</div><p><strong>Read Our Latest Stock Report on Adagene</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Adagene 的最新股票报告</strong></p>
</div><h2>Adagene Stock Performance</h2>
<div class="lb-trans"><h2>Adagene 股票表现</h2>
</div><p>Shares of NASDAQ:ADAG opened at $4.00 on Thursday. The company has a fifty day simple moving average of $3.40 and a 200 day simple moving average of $2.41. Adagene has a 12-month low of $1.30 and a 12-month high of $4.75.</p>
<div class="lb-trans"><p>NASDAQ:ADAG 的股票在星期四开盘时为 $4.00。该公司的 50 日简单移动平均线为 $3.40，200 日简单移动平均线为 $2.41。Adagene 的 12 个月低点为 $1.30，12 个月高点为 $4.75。</p>
</div><p>Adagene (NASDAQ:ADAG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.24. The company had revenue of $3.84 million during the quarter, compared to the consensus estimate of $17.50 million.</p>
<div class="lb-trans"><p>Adagene (NASDAQ:ADAG - 获取免费报告) 最近在 4 月 1 日星期三发布了季度财报。该公司报告的每股收益为（$0.04），超出分析师的共识预期（$0.28）$0.24。该季度的收入为 $3.84 百万，而共识预期为 $17.50 百万。</p>
</div><h2>Institutional Trading of Adagene</h2>
<div class="lb-trans"><h2>Adagene 的机构交易</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Marex Group plc bought a new stake in Adagene during the second quarter valued at $47,000. SmartHarvest Portfolios LLC bought a new position in shares of Adagene during the fourth quarter worth about $73,000. Citadel Advisors LLC bought a new position in shares of Adagene during the third quarter worth about $80,000. Gordian Capital Singapore Pte Ltd grew its position in shares of Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock worth $96,000 after acquiring an additional 24,342 shares during the last quarter. Finally, Fifth Lane Capital LP grew its position in shares of Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company's stock worth $274,000 after acquiring an additional 117,500 shares during the last quarter. Institutional investors own 9.51% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。Marex Group plc 在第二季度购买了价值 $47,000 的 Adagene 新股份。SmartHarvest Portfolios LLC 在第四季度购买了价值约 $73,000 的 Adagene 新股份。Citadel Advisors LLC 在第三季度购买了价值约 $80,000 的 Adagene 新股份。Gordian Capital Singapore Pte Ltd 在第三季度将其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 目前拥有 48,342 股该公司的股票，价值 $96,000，此前在上个季度增持了 24,342 股。最后，Fifth Lane Capital LP 在第四季度将其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 目前拥有 145,000 股该公司的股票，价值 $274,000，此前在上个季度增持了 117,500 股。机构投资者持有该公司 9.51% 的股份。</p>
</div><h2>Adagene Company Profile</h2>
<div class="lb-trans"><h2>Adagene 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.</p>
<div class="lb-trans"><p>Adagene Inc. 总部位于中国苏州，是一家临床阶段的生物制药公司，专注于抗体基础治疗的发现和开发，主要用于癌症和免疫相关疾病。公司成立于 2017 年，利用其专有的免疫组学技术平台挖掘人类抗体库，并设计新型单特异性和双特异性抗体。Adagene 的产品线包括多个处于临床前和早期临床开发阶段的候选药物，重点是针对肿瘤微环境和调节免疫检查点以增强抗肿瘤疗效。</p>
</div><p>At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.</p>
<div class="lb-trans"><p>Adagene 研发工作的核心是其 Bihanc™ 抗体平台，该平台结合了组合噬菌体展示、基于结构的设计和人工智能，以优化结合亲和力、特异性和开发性。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Adagene</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Adagene</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADAG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adagene Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Adagene 吗？</h2>
</div><p>Before you consider Adagene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adagene 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Adagene 并不在名单上。</p>
</div><p>While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adagene 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师对天演药业 2026 财年收益的预测